ProscaVax Vaccine Safe for Recurrent Prostate Cancer Patients, Phase 1a/1b Trial Shows

ProscaVax Vaccine Safe for Recurrent Prostate Cancer Patients, Phase 1a/1b Trial Shows
ProscaVax, a cancer vaccine developed by OncBioMune Pharmaceuticals, is safe for the treatment of recurrent prostate cancer patients, data from a Phase 1a/1b trial shows. The vaccine did not cause any serious adverse events, and did not induce any dose-limiting adverse events during the first 30 days after vaccination, meeting the trial’s primary endpoint, according

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *